Search Within

Shanu Modi

  1. "Center for Molecular Imaging and Biotechnology (CMIB)"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (4)
Groups
  1. Breast Medicine Service (13)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (13)
  3. Department of Medicine (13)
  4. GSK Faculty (13)
  5. Solid Tumor Oncology Division (13)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)

More Groups

People
  1. Michael Berger (9)
  2. Clifford Hudis (8)
  3. Sarat Chandarlapaty (8)
  4. Jose Baselga (6)
  5. Maura Dickler (6)
  6. Tiffany Traina (6)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (1)
  5. 2018 (1)
  6. 2015 (5)

More Years

Publications
  1. Cancer Research (5)
  2. International Journal of Radiation Oncology, Biology, Physics (2)
  3. Journal of Clinical Oncology (2)
  4. Cancer Cell (1)
  5. Cancer Discovery (1)
  6. Lancet (1)

More Publications

Publishers
  1. American Association for Cancer Research (6)
  2. American Society of Clinical Oncology (2)
  3. Elsevier Inc. (2)
  4. Cell Press (1)
  5. Elsevier Science, Inc. (1)
  6. Nature Research (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Meeting Abstract

    Liu, B.; Drago, J. Z.; Rao, Y.; Pereira, P. R.; Safonov, A.; Marra, A.; Ahmed, M. S.; Modi, S.; Reis, J. S.; Montemurro, F.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
    Journal Article

    Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • The genomic landscape of endocrine-resistant advanced breast cancers
    Journal Article

    Razavi, P.; Chang, M. T.; Xu, G.; Bandlamudi, C.; Ross, D. S.; Vasan, N.; Cai, Y.; Bielski, C. M.; Donoghue, M. T. A.; Jonsson, P.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
    Meeting Abstract

    Taldone, T.; Pillarsetty, N.; Dunphy, M. P. S.; Gerecitano, J. F.; Caldas-Lopes, E.; Beattie, B.; Peter, R. I.; Kang, Y. L.; Rodina, A.; Yan, P.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save